User profiles for "author:Adrian Ciurea"
Ciurea AdrianVerified email at ciurea.ch Cited by 5718 |
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
D Van Der Heijde, S Ramiro, R Landewé… - Annals of the …, 2017 - ard.bmj.com
To update and integrate the recommendations for ankylosing spondylitis and the
recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial …
recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial …
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
S Ramiro, E Nikiphorou, A Sepriano… - Annals of the …, 2023 - ard.bmj.com
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …
Neutralizing antiviral antibody responses
Publisher Summary Neutralizing antibodies are evolutionarily important effectors of
immunity against viruses. Their evaluation has revealed a number of basic insights into …
immunity against viruses. Their evaluation has revealed a number of basic insights into …
[HTML][HTML] Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
J Muri, V Cecchinato, A Cavalli, AA Shanbhag… - Nature …, 2023 - nature.com
Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse
symptoms, which can persist for months. While antiviral antibodies are protective, those …
symptoms, which can persist for months. While antiviral antibodies are protective, those …
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to …
Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor
necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as …
necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as …
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
C Molnar, A Scherer, X Baraliakos… - Annals of the …, 2018 - ard.bmj.com
Objectives To analyse the impact of tumour necrosis factor inhibitors (TNFis) on spinal
radiographic progression in ankylosing spondylitis (AS). Methods Patients with AS in the …
radiographic progression in ankylosing spondylitis (AS). Methods Patients with AS in the …
[HTML][HTML] Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections
L Hunziker, M Recher, AJ Macpherson, A Ciurea… - Nature …, 2003 - nature.com
Polyclonal hypergammaglobulinemia is a characteristic of chronic inflammatory conditions,
including persisting viral infections and autoimmune diseases. Here we have studied …
including persisting viral infections and autoimmune diseases. Here we have studied …
Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis
SMD Pan, S Dehler, A Ciurea… - Arthritis Care & …, 2009 - Wiley Online Library
Objective Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to …
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to …
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
A Ciurea, A Scherer, P Exer, J Bernhard… - Arthritis & …, 2013 - Wiley Online Library
Objective To evaluate the baseline characteristics of patients with radiographic axial
spondyloarthritis (SpA; ankylosing spondylitis [AS]) and patients with nonradiographic axial …
spondyloarthritis (SpA; ankylosing spondylitis [AS]) and patients with nonradiographic axial …
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
Objective The first 3 months after symptom onset represent an important therapeutic window
for rheumatoid arthritis (RA). This study investigates the extent and causes of delay in …
for rheumatoid arthritis (RA). This study investigates the extent and causes of delay in …